title: A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers.
abstract: This first-in-human randomized, double-blind, placebo-controlled, ascending-single and -multiple oral dose study was designed to evaluate the safety, tolerability, and pharmacokinetics in healthy volunteers of KAE609 (cipargamin; formerly NITD609), a spiroindolone now in trials for malaria treatment. It was studied in single-dose cohorts (1 to 300 mg, including one 30-mg food effect cohort) with 4 to 10 subjects in each cohort and in multiple-dose cohorts (10 to 150 mg once daily for 3 days) with 8 subjects in each cohort. The follow-up period was 6 to 8 days post-last dose. Safety and pharmacokinetics were assessed at scheduled time points during the study. Systemic exposure in terms of the area under the concentration-time curve from 0 h extrapolated to infinity (AUC0-∞) increased in a dose-proportional manner over the dose range of 1 to 300 mg. The AUC from time zero to the time of the last quantifiable concentration (AUClast) and the maximum concentration of drug in plasma (Cmax) also increased in an approximately dose-proportional manner. When administered daily for 3 days, the accumulation ratio on day 3 (the AUC from time zero to 24 h postdosing [AUC0-24] on day 3/AUC0-24 on day 1) was in the range of 1.5 to 2 in the studied dose range (10 to 150 mg) and was consistent with an elimination half-life of around 24 h. Urine analysis for unchanged KAE609 revealed negligible amounts (≤0.01%) were excreted renally. The high fat food intake did not affect the extent of KAE609 absorption (AUC); however, the Cmax was reduced by around 27%. KAE609 was tolerated in this study, with transient gastrointestinal and genitourinary adverse events of mild to moderate intensity (semen discoloration, diarrhea, nausea and abdominal discomfort, dizziness and headache, catheter site hematoma). Gastrointestinal and genitourinary adverse events increased with rising doses.
authors.affiliation: Novartis Institute for Tropical Diseases, Singapore joel.leong@novartis.com.
authors.forename: F Joel
authors.initials: FJ
authors.lastname: Leong
authors.affiliation: Novartis Institutes for BioMedical Research, Beijing, People's Republic of China.
authors.forename: Ruobing
authors.initials: R
authors.lastname: Li
authors.affiliation: Novartis Healthcare Private Limited, Hyderabad, India.
authors.forename: Jay Prakash
authors.initials: JP
authors.lastname: Jain
authors.affiliation: Novartis Pharma AG, Basel, Switzerland.
authors.forename: Gilbert
authors.initials: G
authors.lastname: Lefèvre
authors.affiliation: Novartis Pharma AG, Basel, Switzerland.
authors.forename: Baldur
authors.initials: B
authors.lastname: Magnusson
authors.affiliation: Novartis Institute for Tropical Diseases, Singapore.
authors.forename: Thierry T
authors.initials: TT
authors.lastname: Diagana
authors.affiliation: Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA.
authors.forename: Peter
authors.initials: P
authors.lastname: Pertel
mesh_terms: D000962:Antimalarials / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D064368:Healthy Volunteers; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D013141:Spiro Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*
chemical_list: D000962:Antimalarials; D007211:Indoles; C552304:NITD 609; D013141:Spiro Compounds
references.citation: Lancet. 2012 May 26;379(9830):1960-6
references.pmid: 22484134
references.citation: Curr Pharm Des. 2013;19(2):266-9
references.pmid: 22973887
references.citation: N Engl J Med. 2009 Jul 30;361(5):540-1
references.pmid: 19641219
references.citation: Antimicrob Agents Chemother. 2012 Jul;56(7):3544-8
references.pmid: 22508309
references.citation: N Engl J Med. 2014 Jul 31;371(5):403-10
references.pmid: 25075833
references.citation: Clin Pharmacokinet. 1994 May;26(5):356-73
references.pmid: 8055681
references.citation: J Med Chem. 2012 May 10;55(9):4244-73
references.pmid: 22524250
references.citation: Science. 2010 Sep 3;329(5996):1175-80
references.pmid: 20813948
references.citation: J Med Chem. 2011 Jul 28;54(14):5116-30
references.pmid: 21644570
references.citation: N Engl J Med. 2011 Sep 22;365(12):1073-5
references.pmid: 21992120
references.citation: Nat Rev Microbiol. 2010 Apr;8(4):272-80
references.pmid: 20208550
references.citation: J Clin Pharmacol. 1987 Apr;27(4):304-9
references.pmid: 3680588
references.citation: N Engl J Med. 2008 Dec 11;359(24):2619-20
references.pmid: 19064625
references.citation: Clin Pharmacol Ther. 2006 Aug;80(2):146-58
references.pmid: 16890576
references.citation: J Med Chem. 2010 Jul 22;53(14):5155-64
references.pmid: 20568778
references.citation: Molecules. 2012 Aug 24;17(9):10131-41
references.pmid: 22922283
references.citation: Cell Host Microbe. 2013 Feb 13;13(2):227-37
references.pmid: 23414762
references.citation: Parasitology. 2014 Jan;141(1):66-76
references.pmid: 23746048
references.citation: N Engl J Med. 2009 Jul 30;361(5):455-67
references.pmid: 19641202
references.citation: Br J Clin Pharmacol. 1988 Aug;26(2):179-82
references.pmid: 3207554
references.citation: Andrologia. 1994 May-Jun;26(3):165-6
references.pmid: 8085670